Avalo Therapeutics Inc (AVTX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Avalo Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 18.30 $ — 69% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 144.2% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.56 | -3.53 – -1.77 | 0 | 56.2% | 11 |
| 12/31/2027 | -2.76 | -4.10 – -1.33 | 0 | -8.1% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.66 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.67 | – | 0 | -66.40 | -18,405.70 | -15 | -15 |
| 2025: Q1 | -0.25 | – | 0 | – | – | -10 | -10 |
| 2025: Q2 | -0.40 | -121.10 | 0 | – | – | -11 | -11 |
| 2025: Q3 | -0.58 | -232.90 | 0 | -100.00 | – | -16 | -16 |
| 2025: Q4 | -0.26 | – | 0 | -69.30 | -23,254.20 | -14 | -14 |
| 2026: Q1 | -0.37 | – | 0 | – | – | -18 | -18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -16 | -16 | -5,371.95 | -15 | 0 | 6 |
| 2017 | 28 | 14 | 12 | 1,822.74 | 13 | 28 | 43 |
| 2018 | 18 | -39 | -40 | -3,317.28 | -3 | 21 | 70 |
| 2019 | 7 | -16 | -16 | -809.74 | -19 | 21 | 36 |
| 2020 | 7 | -27 | -64 | -2,489.12 | -41 | 25 | 44 |
| 2021 | 5 | -82 | -84 | -2,331.41 | -71 | 23 | 80 |
| 2022 | 18 | -37 | -42 | -1,062.65 | -27 | -11 | 33 |
| 2023 | 2 | -27 | -32 | -113.58 | -31 | 7 | 21 |
| 2024 | 0 | -69 | -35 | -3.26 | -49 | 133 | 151 |
| 2025 | 0 | -73 | -78 | -5.84 | -51 | 83 | 116 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Avalo Therapeutics, Inc., ein Biotechnologieunternehmen in der klinischen Phase, entwickelt IL-1ß-basierte Behandlungen für immunvermittelte entzündliche Erkrankungen in den USA.
| Employees | 33 |
|---|---|
| Headquarters | Wayne, PA |
| Address | 1500 Liberty Ridge Drive, 19087 Wayne, United States |
| Phone | 410 522 8707 |
| Website | avalotx.com |
| IPO Date | 13. Nov 2015 |
| ISIN | US05338F3064 |
| Stock Split | 1:240 on 12/29/2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Garry A. Neil M.D. | President, CEO & Director | 1954 |
| Mittie Doyle FACR, M.D. | Chief Medical Officer | 1965 |
| Taylor Boyd | Chief Business Officer | 1989 |
| Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board | 1939 |
| Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board | 1965 |
| Christopher Ryan Sullivan CPA | CFO & Head of Investor relations | 1984 |
| Paul C. Varki J.D., M.P.H | Chief Legal Officer | 1973 |
| Ashley Ivanowicz | Senior Vice President of Human Resources | – |
| Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations | – |
| Jennifer Riley | Chief Strategy Officer | 1975 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,000 | 20.00 | 20,000 |
| 27. Jul 2026 | Doyle Mittie | Chief Medical Officer | Other | 1,000 | 12.65 | 12,650 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.